NCT01648556|CompletedDMC
Research of Predictive Factors to Immune Thrombopenic Purpura
PREDI-PTI
Loading search results
PREDI-PTI
Sponsor study identifier
interventional
37
1 country
1
Study Start
January 15, 2013
Actual (reported)Primary Completion
December 28, 2022
Actual (reported)Study Completion
December 28, 2022
Actual (reported)It is about a multicentric study prospective of more than patients' 60 years with a thrombopenia isolated of less than 100 G/L blood platelet without cause found to estimate so certain examinations realized in the diagnosis (medullary cytogenetics, dosage of the TPO, the Anti-platelet antibodies, isotopic lifetime of platelet) are in favour of the diagnosis of PTI.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 28, 2022
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 20, 2012
Actual (reported)July 24, 2012
Actual (reported)January 15, 2013
Actual (reported)December 28, 2022
Actual (reported)December 28, 2022
Actual (reported)the result of cytogenetics medullary
the primary endpoint corresponds to the occurence of the PTI after two years after inclusion.
two years after inclusion
dosage of the TPO
EVERY 4 MONTHS (followed every four months during two years apres inclusion)
the result to the antibodies antiplatelet (positive or negative) for MAIPA
EVERY 4 MONTHS (followed every 4 months during two years after the inclusion)
The isotopic lifetime of platelet
EVERY 4 MONTHS (followed every four months during two years apres inclusion)
The test in corticoids by the prednisone per os
EVERY 4 MONTHS (followed every 4 months during two years after the inclusion)
Patients of 60 years old and more presenting a thrombopenia isolated with a rate of platelet \< 100 G/l Blood tests and bone marrow biopsy repeated
Blood tests are realized for the dosage of the TPO, the dosage of the antiplatelet antibodies, to measure isotopic lifetime of platelet. The test in corticoids by the prednisone per os is realized too. The bone marrow biopsy is realized at the inclusion and during follow-ups if the haemogram is abnormal.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
CHU Amiens
Amiens, 80000, France
Jean Pierre MD MAROLLEAU, phD
CHU AMIENS
mathilde HUNAULT BERGER, Ph D
University Hospital, Angers
NADINE MAGY BERTRAND, PH D
Centre Hospitalier Universitaire de Besancon
Olivier FAIN, PH D
HOPITAL JEAN VERDIER, BONDY
37 participants (actual enrollment reported by the registry).
First Submitted
July 20, 2012
First Posted
July 24, 2012
Study Start
January 15, 2013
Actual (reported)Primary Completion
Contact the study team to confirm eligibility.
BRIGITTE PAN PETESCH, D
CHU BREST
MICHEL LEPORRIER, PH D
University Hospital, Caen
BERTRAND GODEAU, PH D
CHU CRETEIL
PHILIPPE BIERLING, PH D
EFS IVRY SUR SEINE
LOUIS TERRIOU, PH D
CHRU LILLE
JEAN MARC DURAND, PH D
LA CONCEPTION MARSEILLE
December 28, 2022
Actual (reported)Study Completion
December 28, 2022
Actual (reported)Last Updated
March 12, 2026
Record last verified: 2026-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: